Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn\u27s Disease. by Veerappan, Sundaram G et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Anatomy Articles Department of Anatomy
1-7-2015
Adalimumab Therapy Has a Beneficial Effect on
Bone Metabolism in Patients with Crohn's Disease.
Sundaram G. Veerappan
Royal College of Surgeons in Ireland
Martin Healy
St. James's Hospital, Dublin
Bernard J. Walsh
St. James's Hospital, Dublin
Colm A. O'Morain
Adelaide & Meath Hospital, Dublin
Jacqueline Daly
Royal College of Surgeons in Ireland, jdaly@rcsi.ie
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Anatomy at e-publications@RCSI. It has been accepted for inclusion in
Anatomy Articles by an authorized administrator of e-publications@RCSI.
For more information, please contact epubs@rcsi.ie.
Citation
Veerappan SG, Healy M, Walsh BJ, O'Morain CA, Daly JS, Ryan BM. Adalimumab Therapy Has a Beneficial Effect on Bone
Metabolism in Patients with Crohn's Disease. Digestive Diseases and Sciences. 2015 Jul;60(7):2119-29.
Authors
Sundaram G. Veerappan, Martin Healy, Bernard J. Walsh, Colm A. O'Morain, Jacqueline Daly, and Barbara M.
Ryan
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/anatart/68
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/anatart/68
"This is the peer reviewed version of the following article: Adalimumab Therapy Has a 
Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease. Digestive 
Diseases and Sciences 03/2015; 60(7) , The final publication is available at Springer 
via http://dx.doi.org/ DOI:10.1007/s10620-015-3606-z’. 
 
TITLE PAGE 
 
Title: Adalimumab therapy has a beneficial effect on bone metabolism in patients with 
Crohn’s disease. 
 
Authors: Sundaram G. Veerappan, Martin Healy, Bernard J. Walsh, Colm A. O Morain, 
Jacqueline S. Daly, Barbara M. Ryan.  
 
E-mail and Postal address of authors: 
Sundaram G. Veerappan;   Division of Biology, Department of Anatomy, Royal Col-
lege of Surgeons in Ireland, Dublin 2, Republic of Ireland & Department of Gastroenter-
ology, Adelaide & Meath Hospital, Tallaght, Dublin 24, Republic of Ireland; 
sveerappan78@gmail.com  
Martin Healy; Department of Biochemistry, St. James’s Hospital, Dublin 8, Republic of 
Ireland; mhealy@stjames.ie 
Bernard J. Walsh; Department of Gerontology, St. James’s Hospital, Dublin 8, Republic 
of Ireland; jbwalsh@tcd.ie 
Colm A. O’Morain; Department of Gastroenterology, Adelaide & Meath Hospital, 
Tallaght, Dublin 24, Republic of Ireland; gastroenterology@amnch.ie 
Jacqueline S. Daly; Division of Biology, Department of Anatomy, Royal College of 
Surgeons in Ireland, Dublin 2, Republic of Ireland Republic of Ireland; jdaly@rcsi.ie 
Barbara M. Ryan; Department of Gastroenterology, Adelaide & Meath Hospital, 
Tallaght, Dublin 24, Republic of Ireland; barbara.ryan2@amnch.ie 
 
Corresponding author: Dr. Sundaram G. Veerappan 
 
Declaration of personal and funding interests:  None. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT  
 
Background:   
Infliximab have been shown to have beneficial effects on bone metabolism in patients 
with Crohn’s disease (CD) although as yet the exact mechanisms have not been fully elu-
cidated.  
 
Aim:   
To evaluate the impact of Adalimumab therapy on bone metabolism using a combined in 
vivo and in vitro model.  
 
Methods:  
Parathyroid hormone, Vitamin D, bone formation markers, bone resorption marker, pro-
inflammatory cytokines, anti-inflammatory cytokines, osteoprotegerin and sRANKL 
were measured in control patients, and pre and post treatment with Adalimumab in CD 
patients. The effect of control patients’ and pre and post treatment CD patients’ sera on 
human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation were also ana-
lysed.  
 
Results:  
There was a significant increase in bone formation markers osteocalcin (P < 0.05) and 
pro-collagen type 1 N propeptide (P < 0.01) at 1 and 3 months post treatment. Moreover 
there was a sustained but not significant fall in serum CTx, a bone resorption marker. No 
significant change was seen over time with other parameters measured.  Serum from pre-
Adalimumab treatment Crohn’s patients increased osteoblast viability compared to post 
treatment sera at 6 months (P = 0.002) and controls. However post-Adalimumab treat-
ment sera at 6 months appeared to increase osteoblast differentiation (P = 0.001), which 
is likely to be important in new bone formation.  
 
Conclusions:  
This first study evaluating the role of Adalimumab as a possible bone protector in 
Crohn’s disease patients has shown that similar to infliximab, Adalimumab has complex 
and potentially beneficial effects on bone metabolism. 
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BODY OF PAPER 
 
INTRODUCTION 
         Osteoporosis in patients with inflammatory bowel disease (IBD) is common and 
was first reported approximately 30 years ago [1]. 
  
As many as 75% and 40% of IBD pa-
tients are osteopenic (T-score <-1) [2], and osteoporotic (T-score <-2.5) [3]
 
at the spine 
and at the femoral neck respectively.
 
 In a recent population based cohort study, the rela-
tive risk of hip fracture was 1.41 (0.94-2.11) for ulcerative colitis and 1.68 (1.01-2.78) for 
CD patients [4].   
    The pathogenesis of reduced bone mineral density (BMD) in IBD is multi-factorial. 
Factors such as age, gender, oestrogen deficiency, alterations in calcium homeostasis, 
nutritional and dietary factors, smoking, alcohol and immobility are all likely to play a 
role, as in the general population. However, current evidence suggests that these effects 
and associations are relatively weak and are overshadowed by the effect of the IBD itself 
[5]. Findings that newly diagnosed patients with untreated CD have reduced BMD [6], 
suggests that demineralization in patients with IBD may also occur as a direct conse-
quence of intestinal inflammation. Elevated pro-inflammatory cytokines have been impli-
cated in the pathogenesis of bone resorption in rheumatoid arthritis and postmenopausal 
osteoporosis [7,8].
  
 
    
Circulating pro-inflammatory cytokine levels have of course also been shown to be ele-
vated in IBD patients with active inflammation [9-11]
 
suggesting that disease activity and 
high cytokine levels could also play a role in IBD-related bone mineral density loss. A rat 
model of colitis was associated with a dramatic 33% loss in trabecular bone and an even 
greater suppression in bone formation rate [12].
 
Healing of colitis was associated with an 
increased bone formation rate and a return of bone measurements to normal levels. Serum 
from children with CD was shown to affect bone mineralization in an organ culture mod-
el without altering bone resorption [13].
 
These observations suggest that mediators pro-
duced during intestinal inflammation may alter osteoblast function and bone formation.  
     It has been observed that osteoporotic patients with IBD have higher serum interleukin 
(IL)-6 levels than non-osteoporotic patients [10].
 
Tumour necrosis factor (TNF)-α, IL -1β 
and IL-6, amongst others, are potent activators of bone resorption at low concentrations 
in vitro [14,15].
 
These interactions suggest that TNF blockade may have beneficial ef-
fects on bone generally.  
   To date, data describing the effects of in vivo TNF-α inhibition on general bone metab-
olism in patients with IBD are still limited and restricted to infliximab treatment [16-20].
 
These studies have shown that infliximab appears to have a beneficial effect on bone me-
tabolism in CD patients. The beneficial effects appear to be primarily due to an increase 
in bone formation, while reduction in bone resorption seems to play a lesser role [17,18].
 
These effects seem to be independent of whether the patients are classified as responders 
or non-responders to infliximab treatment based on clinical scores, and of whether the 
patients are on steroid therapy [16-18].
 
Patients who received infliximab have also been 
shown to have increased BMD based on DXA findings [21-23].
 
It’s likely that several 
different mechanisms play a role in this positive effect of infliximab on bone metabolism.  
     Adalimumab is a human IgG1 monoclonal antibody specific for human TNF and is 
used for the treatment of active CD.  To date, there are no published data investigating 
the effect of Adalimumab on bone metabolism in IBD patients. However a recently pub-
lished study in rheumatoid arthritis patients showed an improvement in BMD in 
Adalimumab treated patients over a 4 year period [24]
 
indicating that Adalimumab may 
have similar effect to infliximab on bone metabolism. The aim of our study was to ex-
plore the effects of Adalimumab treatment on bone metabolism in active CD patients by 
measuring the effect of induction/maintenance Adalimumab therapy on biochemical 
markers of bone turnover, bone nutrients, pro-inflammatory cytokines, anti-inflammatory 
cytokines and osteoclastogenesis markers. We also examined in an in vitro model the ef-
fect of sera of Adalimumab treated patients on human osteoblast cell cultures and com-
pared to the effect of healthy control sera on the same cell cultures.   
 
MATERIALS AND METHODS 
Study design and protocol     
       
     This study was a prospective, single centre open label study involving moderate-to-
severe CD patients who failed to respond to conventional medical therapy (5-
aminosalicylates, Mercaptopurine or azathioprine) or who had lost response or were non 
responders to infliximab and who were started on Adalimumab therapy. This study was 
reviewed and approved by our institution’s ethics committee and included a healthy con-
trol population matched for age and sex with our IBD patients.  
 
Patients 
     Twenty patients with CD who received Adalimumab were studied. Inclusion criteria 
included: a confirmed diagnosis of CD using conventional methods, Adalimumab naïve, 
at least 12 weeks since last dose of infliximab before commencing Adalimumab (if re-
ceiving Adalimumab due to loss of response or intolerance to infliximab), normal serum 
calcium and phosphate levels, stable drug regime for the previous 2 months and active 
disease. Active disease was defined as one of the following: a single or multiple perianal 
or enterocutaneous draining fistula(e) as a complication of CD, resistant to conventional 
treatment for at least 3 months; moderate-to-severely active CD based on Crohn’s disease 
activity index (CDAI) and confirmed by radiography or endoscopy; disease refractory or 
dependent on oral (> 7.5mg/day prednisolone or 3mg budesonide) and/or non-responding 
to immunosuppressive agents (azathioprine, Mercaptopurine or methotrexate). Patients 
with confounding factors such as concomitant bone diseases (including Paget, 
osteomalacia, hyperparathyroidism and other endocrinopathies with bone alterations), 
and chronic alcoholism were excluded from this study.   
     All patients had active disease despite standard therapy. Adalimumab was given sub-
cutaneously using an induction regime of 160mg at week 0, 80mg at week 2, and 40mg 
every other week thereafter. Patients receiving Adalimumab were followed up for 6 
months post commencement of treatment and sera were obtained prior to each injection 
at baseline, 1 month, 3 month, and 6 month and for analysis. Disease activity was as-
sessed using the CDAI. 
 
Control patients 
    Twenty healthy normal controls matched for age and gender with our CD patients were 
also studied. People with confounding factors as described previously were excluded 
from acting as controls in this study. Control patients’ sera were obtained on a once-off 
occasion for analysis. Patient and control characteristics are shown in Table 1.    
 
Laboratory analyses  
         All blood samples obtained from the subjects in this study were early morning fast-
ing blood samples. Total procollagen type 1 N-terminal propeptide (P1NP) and N-MID 
Osteocalcin (OC) were chosen as markers of bone formation and C-telopeptide of type-1 
collagen (CTx) serum concentration as a marker of bone resorption. The pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α were measured along with the anti-
inflammatory cytokines; IL-10 and IL-13. OPG and sRANKL were measured as markers 
for osteoclastogenesis. All samples and standards were assayed using the appropriate En-
zyme-linked immunosorbent assay techniques in duplicates and average reading was ob-
tained for analysis. Parathyroid hormone (PTH) levels were measured using the Elecsys 
intact PTH assay and Vitamin D was measured using the DiaSorin 25-hydroxycalciferol 
assay. C-reactive protein (CRP) was measured using standard methods.  
 
Dual Energy X-ray absorptiometry (DXA) 
 
     All BMD measurements were obtained by DXA scan at our institution’s diagnostic 
imaging department. All BMD readings were carried out by a single radiologist to reduce 
variability from the use of different densitometers and inter-observer variability. Meas-
urement of BMD were assessed at the posterior-anterior spine (region L1-L4) and left 
femur (region neck) using the local reference population provided by the manufacturer of 
the DXA machine. Osteopenia and osteoporosis were defined according to World Health 
Organization recommendations. 
 
In-vitro studies (cell source) 
         The osteoblast cell line used in this study was the hFOB 1.19, Homo sapiens (Hu-
man) fetal osteoblast 1.19. This conditionally immortalized cell line was established with 
the temperature sensitive expression vector pUCSVtsA58 and the neomycin resistance 
expression vector pSV2-neo. This cell line has also been shown to be capable of 
osteoblastic differentiation, and to demonstrate osteoblast physiology and cytokine ef-
fects on osteoblasts [25].  
 
In-vitro studies (cell viability)  
      Cell viability was measured using the alamarBlue assay. The alamarBlue assay incor-
porates a fluorometric/colorimetric growth indicator based on detection of metabolic ac-
tivity. Specifically, the system incorporates an oxidation-reduction (REDOX) indicator 
that both fluoresces and changes colour in response to chemical reduction of growth me-
dium resulting from cell growth [26]. Briefly, a 100μl of 0.5 x 106 cells/ml concentration 
was pipetted in triplicate onto a 96 well plate. 3 x 96 well plates were prepared for read-
ing the viability at Day 2, Day 7 and Day 14 incubations. The 96 well plates were incu-
bated at 34
o
C for 24 hours. After 24 hours, the waste media from each of the wells were 
removed. 100μl of serum free media (SFM) was then added in the wells that contained 
cells and left incubated for further 24 hours. Following 24 hours of incubation, SFM was 
removed from each of the wells and 10% serum from study subjects was added into the 
wells in triplicates. The day of serum exposure on the hFOB 1.19 cells were taken as day 
0 of incubation. After 2 days of incubation, i.e. on Day 2, 10μl of alamarBlue was added 
into in 96 well plates labeled Day 2. The plate was then incubated for 4 hours at 34
o
C and 
the absorbance was read on a spectrophotometer at 540nm and 620nm. The viability of 
each of the wells was calculated as described by the manufactures. The media was 
changed every 3 days for this entire experiment. On Day 7 and Day 14 of incubation re-
spectively, the appropriate plate’s absorbance was read as previously.  
 
In-vitro studies (cell functionality)  
     A marker of early-stage differentiation by the human osteoblast cell is the expression 
of the alkaline phosphatase (ALP) which aids bone formation. The p-Nitrophenyl Phos-
phate (pNPP) solution based assay was used in this study to measure ALP production. 
This assay is based on the principle of ALP hydrolysis of p-Nitrophenyl Phosphate to p-
Nitrophenyl.  pNPP is a chromogenic substrate for alkaline and other phosphatases. The 
reaction yields p-nitrophenol, which becomes an intense yellow soluble product under 
alkaline conditions and can be measured at 405 nm on a spectrophotometer.  
     As previously described in cell viability experiments, similarly 3 x 96 plates were pre-
pared with cells. After 2 days of incubation, i.e. on Day 2, the media was removed from 
the wells that contains cells in Day 2 plate and rinsed twice with 100μl of phosphate 
buffer solution. Following this 100μl of pNPP assay was added into each well and the 
plate was incubated for 30 minutes in a 34
o
C incubator and the absorbance was read at 
405nm.  The media was changed every 3 days for this entire experiment. On Day 7 and 
Day 14 of incubation respectively, the appropriate plate’s absorbance was read as de-
scribed above.  
 
Statistical analysis 
     Calculations were made with SPSS version 17.0 software. All data were initially ana-
lysed to see if they were parametric or non-parametric in distribution. Paired Student’s t-
test was used in parametric distribution cohorts and Wilcoxon Signed Ranks test was 
used in non-parametric distribution cohorts to compare values at baseline and after 1 
month, 3 months and 6 months of CD treated Adalimumab patients. Independent Stu-
dent’s t-test was used in parametric distribution cohorts and Mann- Whitney test was used 
in non-parametric distribution cohorts to compare values between the control population 
and baseline in CD treated Adalimumab patients. A P value of < 0.05 was considered 
significant. The results are presented as mean +/- SD.  
 
RESULTS 
Patient’s characteristics 
Duration of disease 
 
The mean CD duration (+/- SD) was 6.45 +/- 6.77 years (range 0.1-27 years).    
 
 
 
Doses of antecedent treatment: 
 The majority of the CD patients were on 5-ASA maintenance therapy (70%) and nearly 
half were on immunomodulators (9/20; 7 of these were azathioprine and the remaining 2 
were on Mercaptopurine). The 5-ASA was commenced in all patients at the time of their 
respective initial diagnosis and the immunomodulators were introduced in the 9 patients 
at a mean (+/- SD) of 4.1 +/- 6.47 years (range 0-17 years) from the time of their initial 
diagnosis. Of the 9 patients who were on immunomodulators; 6 had ileo-colonic disease, 
2 had fistulizing disease and 1 had colonic disease.  
 
Concurrent diseases: 
 
Of the 20 CD patients, 3 patients had other concurrent diagnosis (1 had known diagnosis 
of ankylosing spondylitis made 23 years prior to the CD diagnosis; 1 had a diagnosis of 
lactose intolerance and 1 patients had a diagnosis of non-specific connective tissue dis-
ease).  
 
Nutritional status: 
 
The mean body mass index provided in our Table 1 indicates that our CD patients had 
mean BMI within the normal range. 18/20 (90%) patients had a normal albumin level 
prior to commencement of Adalimumab. Of the remaining 2 patients in whom the albu-
min levels were low, one patient was noted to have severe nutritional deficiency as doc-
umented by albumin level of 17 pre -treatment and the other patient had moderate defi-
ciency with an albumin level of 28 pre-treatment. Other causes of hypoalbuminaemia 
were excluded. 
 
Individual actual treatment for CD or other disorders: 
 
All the medications each of the CD patients were taking during the study is provided in 
Table 2 (Sub-analysis of patient’s characteristics). 
 
Control patient’s characteristics 
 
Two of the control patients had a known diagnosis of hypertension which was well con-
trolled on single antihypertensive agents at the time of inclusion in the study (both of 
them had a normal DXA). The remaining 18 control subjects had no documented or other 
known diseases at the time of their enrolment in this study and were not on any regular 
medications. Of the 20 control patients, two patients had a distant history of a short one 
week course of corticosteroid use for chest infections. All patients had a normal clinical 
examination and normal blood parameters prior to inclusion. 7 of the control patients 
were current smokers with the mean +/- SD years of smoking being 16 +/- 7.2 years 
(range 10-30 years) and further 4 control patients were previous smokers with the mean 
+/- SD stopping smoking being 5.65 +/- 9.57 years (range 0.6 - 20 years). 
 
 
Disease activity 
     The mean disease activity measured by CDAI score appreciably decreased from 
304.65 at baseline to 113.7 after 1 month, 61.65 after 3 months and 27.7 after 6 months 
(P  < 0.001 at all time points compared with baseline) (Figure 1A). To investigate any 
relationship between disease activity and change in bone metabolism markers, patients 
were stratified into those with a fall in CDAI of 70 -100 points (n=5), 100-150 points 
(n=4) and those with 150 points or greater (n=11) at 1 month after treatment with 
Adalimumab. Mean CRP (mg/L) at baseline was 15.92 and fell significantly following 
Adalimumab therapy at all time points measured (P < 0.05) (Figure 1B). At baseline, 16 
patients were not on steroids and 4 patients were on steroids with a mean dosage of 4.2. 
At 6 months, only 1 patient remained on steroids with a mean dosage of 0.125. Although 
a trend was observed, the mean dosage of steroid that patients were on at 6 months did 
not fall significantly (P = 0.098) following treatment. (Figures not shown). 
 
Bone mineral density in active CD patients compare to control 
     Four of 20 CD patients had osteoporosis (T score ≤ -2.5) and further 10 patients had 
osteopenia (T score of -1.0 to -2.5) prior to Adalimumab treatment. In control patients 
two of 20 patients had osteoporosis (T score ≤ -2.5) and further 11 patients had osteo-
penia (T score of -1.0 to -2.5) (Figure 2). The two control patients who had osteoporosis 
were both males and were ex-smokers of 20pack and 6 year respectively.  The mean +/- 
SD of the DXA in the control group is -1.3 +/- -0.9 (range from - 0.3 to -3.8) and in the 
CD group is -1.5 +/- -1.1 (range from -0.1 to -3.8). 
 
The effect of Adalimumab on bone markers  
     Bone formation markers, OC and P1NP (ng/ml) were significantly increased at 1 
month (P = 0.015 and P = 0.008 respectively) and 3 months (P = 0.038 and P = 0.006 
respectively) compared to baseline, but not at 6 months (Figure 3A and 3B). The bone 
resorption marker, CTx serum (ng/ml), decreased from baseline (0.312) to 1 month 
(0.3051) and remained decreased for the remaining 6 months (0.2734), but this decrease 
was not statistically significant (Figure 3C). Serum concentration of OC was lower in CD 
before Adalimumab treatment than in controls while they returned to normal levels after 
Adalimumab treatment (Figure 3A). Surprisingly, P1NP levels were lower and CTx se-
rum levels were higher in controls compared to CD patients at baseline, although these 
differences were not statistically significant. (Figure 3 B-C).  
 
The effect of Adalimumab on bone nutrients  
     At baseline CD patients had lower Vitamin D levels and higher PTH levels compared 
to controls (48.02 nmol/L compared to 53.45 nmol/L and 35.08 pg/ml compared to 24.85 
pg/ml respectively). However this was not statistically significant. With Adalimumab 
treatment, both PTH and Vitamin D levels showed a non significant trend towards in-
crease at 6 months (figures not shown).  
 
The effect of Adalimumab on serum cytokines  
     Overall, changes in serum pro-inflammatory (IL-1β, IL-6 and TNF-α) and anti-
inflammatory (IL-13 and IL-10) cytokines from baseline to 6 months were not statistical-
ly significant. Control patients had a lower serum levels of all the cytokines measured 
compared to CD patients at baseline (figures not shown). 
 
The effect of Adalimumab on osteoclastogenesis markers   
     Serum levels of RANKL and OPG decreased after Adalimumab therapy. At baseline, 
both OPG and RANKL levels were higher in CD patients compared to control, and with 
therapy the levels decreased towards that of control. None of these measured changes 
reached statistical significance however (figures not shown).  
  
The effect of Adalimumab on human osteoblast cell viability 
     Pre-treatment CD sera were associated with increased viable osteoblast cell number 
compared to controls, and Adalimumab treatment resulted in a reduction in viability back 
towards control levels (Figure 4A). Exposure of hFOB cells to CD sera pre and post 
Adalimumab treatment showed that compared to pretreatment baseline sera, post treat-
ment sera reduced in vitro hFOB viability at all time points measured. However the effect 
was significant only for 6 months post commencement of treatment at day 14 of incuba-
tion.  
 
The effect of Adalimumab on human osteoblast cell functionality  
     Osteoblasts exposed to control sera secreted significantly higher levels of ALP than 
those exposed to pretreatment, baseline CD sera (P < 0.001 at Day 2, P < 0.001 at Day 7 
and P = 0.001 at Day 14). Post Adalimumab treatment sera resulted in higher levels of 
ALP secretion from osteoblasts than pretreatment baseline sera and this reached signifi-
cance at 6 months of Day 14 exposure (P = 0.001). Moreover, ALP secretion following 
exposure to post treatment CD sera, no longer differed from the levels secreted following 
exposure to control sera (Figure 4B).   
 
DISCUSSION  
     In this study, we show that Adalimumab treatment had a favorable effect on bone me-
tabolism in patients with active CD. There was a significant and rapid increase in OC and 
P1NP, markers of bone formation, and a decrease, albeit non-significant, in sCTx, a 
marker of bone resorption. Our results are comparable to those found in studies looking 
at the effect of infliximab on bone metabolism in CD patients [17,18].
 
These favourable 
effects were not associated with baseline CDAI’s, DEXA findings, disease location, con-
comitant medical therapy, previous TNF-α exposure, current steroid therapy or indeed on 
biological response to Adalimumab. Although the control group had a lower PINP and a 
higher CTx than CD patients pretreatment this was not statistically significant. However 
the other bone formation marker measured osteocalcin was noted to be lower in CD pa-
tients before treatment compare to control. Most importantly, a rise was noted in the for-
mation markers, and a decrease was noted in the resorption marker with Adalimumab 
therapy which is the main study outcome measured. The number of patients and controls 
in this study was relatively small, and it was an unanticipated that so many controls 
would prove to have low BMD. It would certainly be interesting to study these markers in 
a larger group of age- and sex –matched controls who have documented normal BMD to 
see if in that instance  higher baseline PINP and lower CTx would be found in controls 
compared to patients. This will be studied in future, larger studies. 
Although one might have expected improvement in bone nutrients with Adalimumab 
therapy secondary to increase in absorption of the critical nutrients required for bone 
modelling and increased dietary intake with overall clinical improvement, our study 
failed to show any significant effect. Interestingly, even our control patients had below 
normal Vitamin D levels (defined as ≥ 80nmol/l); again highlighting that Vitamin D in-
sufficiency and deficiency is a pandemic problem. 
     We found a non-significant trend towards higher levels of OPG and sRANKL in CD 
patients at baseline, compared to controls and those levels of OPG and sRANKL de-
creased after Adalimumab therapy. Although these results did not reach significance, 
they are consistent with findings of two previous studies which reported firstly higher 
concentrations of OPG in active CD patients compared to healthy controls [27]
 
and sec-
ondly, decrease OPG levels following infliximab therapy [28].
 
The fact that similar, albeit 
at first glance somewhat counterintuitive changes have been reported after treatment with 
two different anti TNF-α treatments, suggest that the observed changes may be a group 
effect of TNF-α blockade. Therefore given the fact that healthy subjects have both lower 
OPG and sRANKL compared to active CD at baseline, and that Adalimumab therapy 
leads to a decrease in both parameters to approximate levels of control subjects, it would 
appear that the inflammatory response leads to counter-regulatory changes in bone ho-
meostasis controls and that dampening down the inflammatory response with biologic 
therapy leads to a re-setting of the controls towards normal. However, given the lack of 
statistical significance, these results cannot be over interpreted.  
     It has been suggested that bone loss in IBD patients is a result of cytokines (IL-1, IL-6 
and TNF-α) released from inflamed intestine directly influencing osteoblast and osteo-
clast function [12,28].
 
In this study there was no significant association found between 
the serum cytokine levels and bone turnover markers or Adalimumab therapy. Our pa-
tient numbers were small, and larger studies might well find such an association. Howev-
er, a previous study in patients treated with infliximab found that mucosal but not system-
ic measurements of pro-inflammatory cytokines mirrored response to therapy [29].
 
We 
did not measure mucosal cytokine levels in this study. 
     The results of our in vitro studies are particularly interesting. Exposure of osteoblasts 
to sera from active CD-Adalimumab treated patients showed consistently higher levels of 
viable cells compared to control subjects at every time point measured. Therapy led to a 
decrease in viability levels towards those of controls. This suggests that Adalimumab 
treatment does in fact have an effect of osteoblast activity. Higher osteoblast cell viability 
observed pretreatment is most likely an inflammatory driven response. More important 
than osteoblast cell viability alone however, is osteoblast differentiation and functionali-
ty. Although higher osteoblast viability was found pretreatment with Adalimumab, the 
amount of ALP secreted was significantly lower in the pretreatment group CD group 
compared to control patients. ALP is an early differentiation marker of the osteoblasts 
and higher levels found post Adalimumab treatment indicate that the osteoblasts which 
were present, had better functionality. This strongly suggests that Adalimumab treatment 
has a direct effect on the human osteoblasts in vitro and that the increase in bone for-
mation markers identified in vivo is reflection of this beneficial effect. 
We did not look at osteoclast function in vitro as to date there is no good human in vitro 
osteoclast model. 
Two different TNF alpha inhibitors (Infliximab and Adalimumab) have now been shown 
to improve bone metabolism in IBD and also Rheumatoid arthritis patients [24], another 
inflammatory condition. A potential question arises as to whether anti TNF agents might 
also be advantageous in non - inflammatory, age related osteoporosis / osteopaenia? Giv-
en current established therapies for osteoporosis such as bisphosponate therapy or 6 
monthly sub cut Denosumab injection, both of which are widely available and much 
cheaper than the anti -TNF agents, this question is not likely to be addressed for the time 
being.  
Our study has a number of limitations. Firstly, this was not a randomized study and the 
number of patients included was small, therefore meaningful analyses of various sub-
groups were restricted. Secondly, this was a heterogeneous group of medically refractory 
CD patients receiving different parallel medical therapies that may have affected the 
overall effect of Adalimumab therapy on the studied parameters. Thirdly, markers of 
bone turnover, bone nutrients, osteoclastogenesis, and cytokines varied from patient to 
patient in this study, suggesting that the aetiology of bone loss in CD may be heterogene-
ous in nature. However, to counter for this, each patient acted as his/her own control. 
Clinical remission rates were high in this study, and this is likely to be playing a signifi-
cant role in the observed changes. Interestingly, our study did not show significant 
changes in the chosen measured cytokines over the duration of the study, which raises the 
possibility that other pro-inflammatory cytokines may be playing an important role, or 
indeed that this study was too small to detect such changes. Fourthly, BMD was meas-
ured at baseline only, as the study was 6 months in duration and it would be unlikely that 
DXA scans would show any meaningful changes over this time period. Previous studies 
looking at the effects of bisphosphonates therapy on BMD in CD patients only showed 
appreciable change in BMD on DXA after 1 year of therapy [30].
 
Repeat DXA scan after 
more prolonged therapy would be fruitful in future studies of longer duration to see 
whether the beneficial effects on bone formation markers and osteoblast function trans-
late into meaningful improvements in DXA scan, and by extrapolation into reduction in 
fracture risk. Finally, it is debatable as to whether all our control patients can be consid-
ered as ‘real’ controls given that 2 of them had osteoporosis and 11 of them had osteo-
penia based on DXA scan measurement. The fact that more than half of our control pa-
tients were either active smokers or previous heavy smokers is more than likely a major 
contributor to the findings of the very similar DXA results (reduced BMD) amongst pa-
tients and controls. This was an unanticipated  limitation of our study, as although the 
controls appeared physically and biochemically healthy, they may not in fact have acted 
as ‘real’ controls in this particular study outcome. This highlights the fact that even 
among presumed healthy subjects in the general population many people have undetected 
lower BMD and vitamin D levels. However, this sub group of control patients did not 
exhibit significant differences in any of the parameters measured in this study as com-
pared to remaining control patients with normal BMD.  
     Notwithstanding these limitations, this is the first study to have examined the effect of 
Adalimumab on bone metabolism in CD patients. As a result, this is the first study to 
demonstrate that Adalimumab treatment has a beneficial effect on bone metabolism in 
CD patients both in vivo and in vitro and that Adalimumab therapy has a direct effect on 
osteoblasts. The observed effects are similar to some previously reported effects of inflix-
imab therapy and hence are likely to represent a class effect.  While this may have 
seemed intuitive, it is important to have demonstrated this. 
A larger study is needed to confirm these results and to investigate the long-term effect of 
Adalimumab therapy on bone metabolism and bone mineral density. It will also be inter-
esting to assess the effect of cessation of therapy on these parameters and to determine 
whether the effects are transient or enduring. This will be the goal of future studies. 
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 Adalimumab 
treated 
(n=20) 
Control  
group  
(n=20) 
Sex, female, n (%) 12 (60) 10 (50) 
Age (median, years) 35.2 (15-56) 35.7 (21-60) 
Current smokers, n (%) 10 (50) 7 (35) 
Mean body mass index, kg/m
2 24.0 25.1 
IBD-related coincidental medication, n (%)   
Corticosteroids 4 (20) N/A 
5- Aminosalicylic acid 14 (70) N/A 
Mercaptopurine/Azathioprine 9 (45) N/A 
Disease location, n (%)  N/A 
Terminal ileum 5 (25) N/A 
Ileo-colonic 12 (60) N/A 
Colonic 2 (10) N/A 
Fistulizing disease 1 (5) N/A 
Previous infliximab exposure, n (%) 13 (65) N/A 
Other concomitant medications, n (%)  N/A 
Calcium/Vitamin D 6 (30) N/A 
Bisphosphonates 0 (0) N/A 
 
                              Table 1: Patients characteristics (N/A=not applicable) 
 
  
 
 
CD  
pa-
tients 
Duration of 
disease prior to  
commence-
ment of  
Adalimumab 
(years) 
List of 
medications 
Previous 
medications 
(either 
stopped due 
to side effect 
or ineffi-
ciency) 
Other 
diseases 
Nutrition-
al status 
(albumin 
level): 
normal 
>35; mod-
erate defi-
ciency 28-
35; severe 
deficiency, 
25 
Patient 
1 
2 5-ASA; AZA; 
Cal/Vit D; CS 
IFX 
(ineffective) 
None Normal 
Patient 
2 
5 AZA IFX (S/E) None Normal 
Patient 
3 
17 5-ASA; CS; 
Cal/Vit D 
IFX (S/E) None Moderate 
deficiency 
Patient 
4 
11 5-ASA; Multi-
vitamins; 
Lomotil 
(antidiarrhoeal) 
IFX 
(ineffective) 
Certolizuma
b 
(ineffective) 
Ankylosin
g spondyli-
tis (23 
years ago 
prior to CD 
diagnosis 
was made) 
Normal 
Patient 
5 
7 5-ASA; Cal/Vit 
D; Tramadol 
(analgesia) 
None None Severe 
deficiency 
Patient 
6 
5 AZA; PPI 5-ASA 
(ineffective) 
None Normal 
Patient 
7 
0.1 AZA; CS 5-ASA (S/E) Non-
specific 
CTD 
Normal 
Patient 
8 
2 AZA; PPI IFX (S/E) None Normal 
Patient 
9 
9 5-ASA; antihy-
pertensive; B12 
injections 
IFX 
(ineffective) 
None Normal 
Patient 2 5-ASA None None Normal 
10 
Patient 
11 
10 5-ASA AZA (S/E) 
IFX 
(ineffective) 
None Normal 
Patient 
12 
14 5-ASA; 6-MP; 
PPI; SSRI; 
Antiemetics 
AZA (S/E) None Normal 
Patient 
13 
8 5-ASA; 6MP; 
PPI; Cal/Vit D 
AZA (S/E) 
IFX (S/E) 
None Normal 
Patient 
14 
0.8 5-ASA AZA (S/E) None Normal 
Patient 
15 
2 5-ASA AZA (S/E) None Normal 
Patient 
16 
2 None AZA (S/E) 
IFX 
(ineffective) 
None Normal 
Patient 
17 
3 5-ASA; AZA IFX 
(ineffective) 
None Normal 
Patient 
18 
2 CS 6-MP 
(ineffective) 
AZA 
(ineffective) 
IFX (S/E) 
Lactose 
intolerance 
Normal 
Patient 
19 
1 5-ASA; Cal/Vit 
D 
IFX 
(ineffective) 
None Normal 
Patient 
20 
27 5-ASA; AZA; 
Cal/Vit D 
IFX 
(ineffective) 
None Normal 
 
Table 2: Sub-analysis of CD patient characteristics 
Abbreviations: 5-ASA: 5 Aminosalicylic acid; AZA: Azathioprine; 6MP: 6-Mercaptopurine; CS: Cortico-
steroids; Cal/Vit D: Calcium and vitamin D supplements; PPI: Proton pump inhibitors: IFX: Infliximab; 
SSRI: Selective serotonin receptor inhibitors; S/E: side effects 
 
 
 
 
 
 
 
FIGURES 
 
 
 
 
Figure 1A: CDAI scores in control and CD patients                      Figure 1B: CRP levels in control and CD patients  
 
 
 
             
 Figure 2: Distribution of BMD based on DXA score in control and Crohn’s patients 
 
 
 Figure 3 A                                                                            Figure 3 B 
 
 
 
 
 
 
 
                                   Figure 3 C 
 
Figure 3 (A-C) Changes in median Osteocalcin (OC), Pro- Collagen type 1 N propeptide (P1NP) and Carboxyterminal 
N-telopeptide (CTx) serum levels during treatment with Adalimumab.  
 
 Figure 4A: Number of viable hFOB cells on exposure to serum from Adalimumab treated CD and control over 14 days 
 
 
Figure 4B: Amount of ALP secreted on exposure of serum from control and CD Adalimumab treated patients over 
14days  
